Opinion|Videos|December 23, 2024
Final Thoughts: The Spesolimab and GPP Flare Reduction
Key Takeaways
Panelists discuss how the Effisayil 2 trial's results suggest that spesolimab offers a promising strategy for reducing the frequency and severity of GPP flares, potentially revolutionizing the management of this severe and life-threatening condition.
Advertisement
Episodes in this series
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
3
FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA
4
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
5